Patients with severe PTSD may be eligible

Transcend Therapeutic's IMPACT-2 study is accepting patients with severe PTSD who have attempted at least one treatment (psychotherapy or pharmacological).

Early results for the treatment, methylone (MDMC), have shown promising results including more than 80% reduction in PTSD symptoms. Relief was measured within days of treatment and durable for more than 64 days after treatment. The treatment was well-tolerated by all patients in prior studies.

Novelcare can help you evaluate patient eligibility and facilitate patient access.